Bone Care International, Inc.

Opko Renal, LLC

Opko Ireland Global Holdings, Limited

Eirgen Pharma Ltd.

Proventiv Therapeutics, LLC

Cytochroma Inc.

Other

Lunar Corporation

The United States of America As Represented by the Secretary of

Genzyme Corporation

Opko Health, Inc.

Opko IP Holdings Ii, Inc.

Opko Ireland Global Hodlings, Ltd.

Horst, Ronald L.

Koszewski, Nicholas J.

Charles W Bishop

Joyce C Knutson

Eric J Messner

P Martin Petkovich

Keith H Crawford

Richard B Mazess

Jay A White

Samir P Tabash

Stephen Strugnell

Robert M Moriarty

Sammy Asiamah Agudoawu

Joel Z Melnick

Charles R Valliere

Raju A Penmasta

Glenville Jones

Stephen A Strugnell

Liang Guo

Christian F Helvig

Lei Zhao

Ronald L Horst

Timothy A Reinhardt

Nicholas J Koszewski

Sanjay K Singhal

Susan Peers

Sammy A Agudoawu

Hector Floyd Deluca

Martin Petkovich

Phillip Frost

John C Gallagher

Susan H Peers

Hector F Deluca

Sanjay K Singh-Al

Martin P Petkovich

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

Methods of vitamin D treatment

Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D, 25-hydroxyvitamin D, or a combination of 25-hydroxyvitamin Dand 25-hydroxyvitamin D, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D, 25-hydroxyvitamin D, or a combination of 25-hydroxyvitamin Dand 25-hydroxyvitamin D.

Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin Dand 25-hydroxyvitamin D

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin Dwith or without 25-hydroxyvitamin Dand, as necessary, 1,25-dihydroxyvitamin Das a Vitamin D hormone replacement therapy.

Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Adjunctive therapy with 25-hydroxyvitamin D and articles therefor

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing parathyroid levels

Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.

Use of calcifediol in bariatric surgery patients

The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin Dfor 25-hydroxyvitamin D repletion and/or maintenance.

Method of treating and preventing secondary hyperparathyroidism

Methods of treating vitamin D insufficiency in chronic kidney disease

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Methods for controlled release oral dosage of a vitamin D compound

Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3

Some embodiments of a tally stamp device described herein provide a stamp and a counter system. The tally stamp may include an elongate body housing the stamp and counter system.

Tally stamp devices, systems, and methods

Growing community of inventors

Miami Beach, FL, United States of America

Charles W Bishop